Radium Ra-223
- Generic Name
- Radium Ra-223
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
PK in Pts With HRPC & Skeletal Metastes
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT00667537
BAY88-8223, Does Response Study in HRPC Patients
Phase 2
Completed
- Conditions
- Hormone Refractory Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT00667199
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate CancerNeoplasm Metastasis
- Interventions
- Drug: Saline
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT00459654
BAY88-8223, Dose Finding Study in Patients With HRPC
Phase 2
Completed
- Conditions
- Prostate CancerNeoplasm Metastasis
- Interventions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 122
- Registration Number
- NCT00337155
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath